Dubois Marie-Line, Winters Patricia D, Rodrigue Marc-André, Gekas Jean
Faculty of Medicine, Laval University, Quebec City, QC, Canada.
Illumina, Inc., San Diego, CA, United States.
Front Genet. 2023 Apr 18;14:976051. doi: 10.3389/fgene.2023.976051. eCollection 2023.
Noninvasive prenatal testing (NIPT) using cell-free DNA (cfDNA) is typically carried out to screen for common fetal chromosomal anomalies, with the option to screen for a wider range of chromosomal changes (expanded NIPT) becoming increasingly available. However, little is known about pregnant patients' attitudes and preferences regarding expanded NIPT. To address this gap, we surveyed general-risk patients having first-tier cfDNA screening at a private prenatal clinic on their expectations for expanded NIPT. Patients were asked questions regarding their current pregnancy and previous pregnancy history, their opinions on fetal DNA screenings during pregnancy and incidental findings, information and opinions on financial resources for NIPT, as well as socio-cultural questions to determine patient demographics. Of the 200 survey participants, the majority were educated, self-reported as white, had a higher than average income, and reported no aneuploidy risk factors. When asked what information they would like to receive from cfDNA screening, the vast majority of participants wanted all information available that could have an immediate impact on fetal health (88%) or an immediate impact on infant health from birth (82%). Many participants also wanted information that could have a future impact on the child's health or an immediate or future impact on the pregnant woman's own health. Most participants wanted information about the sex of fetus (86%) and common trisomies (71%), with almost half of participants desiring information about rare autosomal aneuploidies and/or all genetic information that may affect the baby. In addition, participants were found to be comfortable screening for conditions that are well-known, influence care during pregnancy, and are treatable. Finally, while most respondents either had insurance coverage for NIPT or were able to afford NIPT out of pocket, the majority of our participants felt that expanded NIPT should be either free for everyone or for those considered high risk. Our findings suggest that with appropriate pre-test counseling, pregnant patients may choose NIPT for an expanding list of conditions.
使用游离DNA(cfDNA)进行的无创产前检测(NIPT)通常用于筛查常见的胎儿染色体异常,而筛查更广泛染色体变化的选项(扩展NIPT)也越来越普遍。然而,对于孕妇对扩展NIPT的态度和偏好知之甚少。为了填补这一空白,我们在一家私立产前诊所对进行一级cfDNA筛查的一般风险患者进行了调查,了解他们对扩展NIPT的期望。询问了患者有关其当前妊娠和既往妊娠史的问题,他们对孕期胎儿DNA筛查和偶然发现的看法,关于NIPT资金来源的信息和看法,以及用于确定患者人口统计学特征的社会文化问题。在200名调查参与者中,大多数人受过教育,自我报告为白人,收入高于平均水平,且报告无非整倍体风险因素。当被问及希望从cfDNA筛查中获得哪些信息时,绝大多数参与者希望获得所有可能对胎儿健康有直接影响(88%)或对出生后婴儿健康有直接影响(82%)的可用信息。许多参与者还希望获得可能对孩子健康有未来影响或对孕妇自身健康有直接或未来影响的信息。大多数参与者想要了解胎儿性别(86%)和常见三体综合征(71%)的信息,近一半的参与者希望了解罕见常染色体非整倍体和/或所有可能影响婴儿的遗传信息。此外,发现参与者对筛查已知的、会影响孕期护理且可治疗的疾病感到放心。最后,虽然大多数受访者要么有NIPT保险覆盖,要么能够自掏腰包支付NIPT费用,但我们的大多数参与者认为扩展NIPT应该对每个人免费或对那些被认为是高风险的人免费。我们的研究结果表明,通过适当的检测前咨询,孕妇可能会为越来越多的情况选择NIPT。